A B S T R A C T IFI16, member of the IFN-inducible PYHIN-200 gene family, modulates proliferation, survival and differentiation of different cell lineages. In particular, IFI16 expression, which is regulated during the differentiation of B cells, was recently studied in B-CLL as well. Here, we compared IFI16 expression in several lymphomas including Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma with respect to normal cell counterparts. We observed that IFI16 expression was significantly deregulated only in mantle cell lymphoma (p < 0.05). Notably, IFI16 was associated with the expression of genes involved in interferon response, cell cycle, cell death and proliferation and, interestingly, lipid and glucose metabolism, suggesting that IFI16 deregulation might be associated with relevant changes in cell biology. In our group of mantle cell lymphoma samples a correlation between patient survival and IFI16 expression was not detected even though mantle cell lymphoma prognosis is known to be associated with cell proliferation. Altogether, these results suggest a complex relationship between IFI16 expression and MCL which needs to be analyzed in further studies.
Introduction
IFI16 belongs to the IFN-inducible PYHIN-200 gene family [1, 2] encoding evolutionary related proteins that share a 200-amino acid signature motif (hematopoietic interferon-inducible nuclear, HIN). IFI16 displays two HIN domains separated by a spacer region the length of which is the result of an alternative mRNA splicing leading to the production of three IFI16 isoforms (A, the predominant isoform; B and C; 3) detectable in several cell types [1] . IFI16 protein localizes both in nucleus and cytoplasm and it is able to either homodimerize or heterodimerize with different partners including BRCA1, TP53, ASC, RB and STING [3, 4, 5, 6, 7, 8] . It is noteworthy that IFI16 binds dsDNA sugar phosphate backbone through its positive charged residues in the HIN domain [9, 10] . Several reports indicated that IFI16 can be considered a DNA sensor involved both in the innate immune response, in particular against viral infections, including HSV-1, HCMV and HIV-1 [11, 12, 13, 14, 15, 16, 17] and in the activation of the interferon gene pathway. Indeed, IFI16 is required for the cGAMP-induced activation of STING, promoting its phosphorylation and translocation [18] . IFI16 and cGAS are involved in the activation of the innate immune response to infections by DNA viruses [6, 16] . The biological role of IFI16 in the cellular biology has been demonstrated by several studies showing that IFI16 regulates proliferation, differentiation, apoptosis/pyroptosis, senescence and inflammation [19, 20, 21, 22, 23, 24, 25, 26] . More specifically, IFI16 has been shown to down-regulate cell proliferation and to elicit apoptosis in several cell types [21, 23, 26] . Consistently, IFI16 negatively regulates the cell cycle through binding and functional modulation of several molecules involved in the cell cycle regulation such as TP53, RB, and p21 [21, 25, 26] . The relationship between IFI16 and differentiation was pointed out during the differentiation of CD34 þ hematopoietic stem cells to lymphoid and monocytic lineages [1, 27] . Furthermore, recent studies have shown that IFI16 expression is modulated in B-cell differentiation [28] . In particular, IFI16 expression is related to B-cell differentiation stages and it is significantly downregulated during both the transition from naive B-cell subsets to proliferating GC cells and the differentiation of GC-cells to plasma cells, whereas IFI16 expression increases during the shift from GC cells to memory cells [28] . IFI16 expression is believed to have an intriguing relationship with key transcription factors, including BCL6, NF-κB, STAT3, and STAT5, involved in central processes of the B-cell biology [28, 29] . Interestingly, gene expression profiling analysis showed that IFI16 expression was inversely related to the expression of the transcription factor BCL6, a master regulator of GC constitution [28, 29] . IFI16 was also studied as prognostic biomarkers in chronic lymphocytic leukemia (CLL) patients. Interestingly, reduced IFI16 expression was linked to a worse clinical outcome when ZAP70 and CD38 molecules were expressed. Probably, the lack of IFI16, associated with an abridged antiproliferative effect, might be particularly severe in cells constitutively receiving an activation/proliferation signaling. Therefore, the balance between IFI16 expression and activation signaling (mediated by ZAP70/CD38) may be a more reliable prognostic parameter [30] .
In this study, we aimed to assess the expression of IFI16 at gene and protein levels in a large series of B-cell derived non-Hodgkin lymphomas (NHLs), aiming to assess IFI16 expression as a possible prognostic marker in these NHLs.
Materials and methods

Case series
We studied the expression of IFI16 gene in a discovery cohort of 198 cases for which gene expression profiles (GEPs) were previously generated (GSE12195) [31] . This data is available on GEO Profiles database (Gene Expression Omnibus of the National Center for Biotechnology Information-NCBI) which stores gene expression profiles derived from 
Immunohistochemistry on tissue microarrays
A Giemsa-stained slide was prepared from each paraffin block containing representative tumor regions marked on every slide. Tissue cylinders with a diameter of 1.0 mm were punched from the marked areas on each block and placed in a recipient paraffin block using a precision instrument as previously described [28, 30] . Punches were performed on areas mainly represented by neoplastic cells based on morphological and immunophenotypic evaluation. Tissue microarrays (TMAs) were then prepared for immunohistochemistry.
We studied IFI16 expression by immunohistochemistry (IHC) on TMAs including 32 cases (in duplicate cores). From each recipient block, 1.5 μm-thick sections were cut and tested with anti-IFI16 mouse monoclonal antibody (Sigma, Milan, Italy, dilution 1:100). Briefly, paraffinembedded sections were dewaxed and submitted to antigen retrieval by heating in Dako PTLink (DakoCytomation, Glostrup, Denmark; code PT100/PT101) in an EnVision Flex Target Retrieval Solution High pH (DakoCytomation; code K8004) at 92 C for 5 min. Sections were incubated at room temperature with fetal calf serum (10 min) and then with the specific primary antibody (for 30 min). Each evaluation was performed by at least two expert hematopathologists blinded to the study. Scores were compared and consensus agreement was reached at the microscope in all cases. Table 3 Genes whose expression is significantly related to that of IFI16 (Pearson correlation >0.5). Immunohistochemistry staining was scored based on the percentage of positive neoplastic cells (visual count performed by two hematopathologists) as follows: 0 ¼ no positive cells; 1 ¼ 1-20%; 2 ¼ 21-40%; 3 ¼ 41-60%; 4 ¼ 61-80%; and 5 ¼ 81-100%. A Semi-quantitative scoring system was used to assess staining intensity and graded as "strong", "weak", and "absent" [32] .
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Micrographs were obtained using an Olympus BX61 microscope equipped with an Olympus DP-70 digital camera. Image acquisition, evaluation and color balance were performed using by CellF software [28, 30] .
Gene expression analyses
Gene expression analysis was carried out as previously reported [31, 33, 34, 35, 36, 37, 38] . Analysis of GEP data in terms of supervised and unsupervised analysis was achieved using GeneSpring GX 12 (Agilent Technologies, Santa Clara, CA, USA). All data were obtained using Affymetrix HG-U133 2.0 plus microarrays (Affymetrix, Inc. http: //www.affymetrix.com/support/index.affx). Briefly, the expression value of each selected gene was normalized to have a zero mean value and unit standard deviation. The distance between two individual samples was determined by Pearson correlation using the normalized expression values. Unsupervised clustering was generated using a hierarchical algorithm based on the average-linkage method. To perform the supervised gene expression analysis, differentially expressed genes between different groups were identified using a two-tails Student t-test and adjusted Benjamini-Hochberg correction for false discovery rate, applying the following filtering criteria: p-value 0.05, and fold change 2.
Gene Set Enrichment Analysis (GSEA) was performed to better understand the potential biological significance of the identified molecular signatures. Briefly, GSEA (also known as functional enrichment analysis) is a method to identify classes of genes that are over-represented in a large set of genes (molecular or gene signature) and may have a functional association with disease phenotypes [39] . GSEA of the interested gene sets was performed in terms of Gene Ontology (GO) Biological Processes, Curated Gene Sets and Hallmark Genes using GSEA MsigDB (www .broadinstitute.org/gsea/msigdb) web-based analysis tool [39] , setting the options to the default (displaying top 10 gene sets with FDR q-value below 0.05).
When we focused our analysis on IFI16 expression, we identified IFI16 expression using three different probe sets (206332_s_at; 208966_x_at; and 208965_s_at) in the HG-U133 2.0 plus microarray. The median value from the three probes was used for the analysis.
Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics 20.0 and Prism (GraphPad softwares, USA). ANOVA and unpaired T-tests were employed. When a sample size was less than 10 cases in at least 1 group, a non-parametric (Mann-Whitney) test was used to analyze the GEP data to compare IFI16 expression in different subgroups. Survival analyses were performed by Kaplan-Meier method. Two-sided tests were used in all calculations. The limit of significance for all analyses was defined as p 0.05.
Results and discussion
IFI16 gene expression is reduced in mantle cell lymphoma
We studied IFI16 gene expression in the cohort of lymphoma cases, including 46 BL, 46 DLBCL, 40 FL, 24 MZL, and 22 MCL cases ( Fig. 1A) . Particularly, we compared gene expression between each tumor type and the corresponding cellular counterpart (i.e. GC cells for BL, FL, and DLBCL and Naïve and/or Memory B-cells for MCL and MZL). Only MCL showed a significant deregulation when compared to the non-neoplastic components (0.123 vs. 0.525; standard error 0.127 vs. 0.059, p ¼ 0.047; Fig. 1B-F, Table 1 ). It should be noted that MCL were compared to both naïve and memory B-cell compartments that represent the postulated counterparts of unmutated and mutated MCL cases, respectively. Since our cases were not distinct based on the immunoglobulin mutational status, naïve/memory subsets have comparable levels of IFI16 [28] , and IFI16 is not differentially expressed in mutated vs. unmutated MCL cases [40] , we were confident that this approach could be considered reliable. A trend toward a reduced expression was also observed in DLBCL; however, the difference was not significant (p ¼ 0.07). Of note, DLBCL were compared to GC only, GEP from plasmablasts, the postulated counterpart of ABC-type DLBCL not being available. Nonetheless, this choice did not seem to affect the analysis since ABC and GCB-type DLBCL did not show differential IFI16 gene expression [41] .
Thereafter, we studied IFI16 expression in a validation cohort of cases. When IFI16 gene expression levels were studied in 64 MCL vs. naïve (N ¼ 5) and memory (N ¼ 5) B-cell samples, an even more evident difference was observed (-0.375 vs. 0.498 vs. 0.544, ANOVA, p-value ¼ 0.002; Fig. 2A ). In fact, again, IFI16 expression levels were higher than in memory (p ¼ 0.01) and naïve (p ¼ 0.009) B-cell subtypes.
To improve the strength of these data, we also studied IFI16 protein expression by immunohistochemistry in a series consisting of 11 BL, 26 DLBCL, 24 FL, 13 MZL, and 32 MCL. We found a variable degree of expression with positive cases ranging from 31% in MZL to 73% in BL. Concerning MCL, 19/32 cases were positive (59%). Noteworthy, the intensity of the staining was strong in all positive cases with the exception of all MCL and a few FL, in which the staining was weak ( Fig. 2B ; Table 2 ). A similar pattern has also been observed in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), the first lymphoid neoplasm in which a weak IFI16 expression was documented [30] . Overall, these data indicate that MCL significantly down-regulates IFI16, even in cases that do not completely abolish its expression.
IFI16 gene down-regulation is associated with increased proliferation and altered metabolism in MCL
We sought to assess whether the expression of IFI16 was associated with the expression of other genes and specific cellular functions. To do so, we studied the transcriptome of B-NHL and normal B-cell subsets, looking for genes with expression levels correlated to those of IFI16. We found 93 genes whose expression was significantly related to that of IFI16 (Pearson correlation >0.5; Fig. 3A ; Table 3 ). Interestingly, at GSEA, they turned out to be significantly involved in interferon response and allograft rejection (as expected based on IFI16 known functions), as well as in other biological processes (Table 4 ). Of interest, these findings were, at least in part, validated by the evidence that several of the identified molecules are indeed expressed in MCL, showing sometimes a reduced expression mirroring that of IFI16, including CD22, BCL11A, FGD2, GPR18, PTPRC, HHEX, PPP1CB, and CTSS [42, 43, 44, 45, 46, 47] .
We then compared the cases with the highest (25 th percentile) or lowest (25 th percentile) IFI16 gene expression with supervised analysis. We found 79 genes differentially expressed in the two groups (Table 5) ; by GSEA they turned out to be significantly involved in cell cycle, cell death and proliferation as well as in other programs (Table 6 ). Furthermore, GSEA indicated that the two groups significantly differed as far as certain biological processes related to metabolism were concerned. Particularly, both lipid and glucose metabolism appeared affected ( Fig. 3B-E ; Table 6 ). Overall, these data indicated that IFI16 deregulation was associated with relevant changes in cell biology. 
IFI16 expression is not related to clinical aggressiveness and survival in MCL
Since IFI16 downregulation appeared to be associated with relevant cellular function modifications [19, 20, 21, 22, 23, 24, 25, 26, 28] , we investigated whether its expression was associated with clinical features. IFI16 gene expression did not significantly differ in indolent (N ¼ 7) vs. classical (N ¼ 15) MCL cases (p ¼ 0.67) (Fig. 4A) . Similarly, IFI16 gene expression was not associated with overall survival when it was evaluated as either continuous variable (Cox-regression, p ¼ 0.785), or by 50 th percentiles (p ¼ 0.5, Fig. 4B ), or by quartile sub-grouping (p ¼ 0.647, Fig. 4C ). This was somehow surprising as MCL prognosis is strictly associated with proliferation [48] , which in turn appeared to be associated with IFI16. However, in CLL the prognostic value of IFI16 reduction was limited to the subgroups of patients presenting with CD38 and/or ZAP70 expression [30] . Therefore, we cannot exclude that further investigation in MCL will unveil a prognostic value for this molecule. 
Conclusion
In conclusion, we found that IFI16 is significantly downregulated in MCL, being associated with relevant cellular modifications such as proliferation increase and metabolism activation. Nonetheless the possible functional value of IFI16 down-regulation remains to be assessed and further studies need to be performed to determine its real role in MCL. Similarly, a more extensive evaluation of its prognostic value, in perspective homogeneous series should be assessed. In fact, our study was not specifically designed for clinical correlates, the series being not homogenous and the treatment variable. Finally, the specific potential impact of IFI16 as a diagnostic marker might be assessed in diagnostic accuracy study. In fact, though probably not useful for differentiating MCL from CLL (similarly down regulating it), it might be more relevant for other differential diagnoses such as, for example, CCND1-MCL vs. CD5þ DLBCL, in addition to SOX11. 
